These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 21874913)

  • 1. [The development of influenza virus-like particle vaccines].
    Zhang LX; Yu ZJ; Zhou JF; Shu YL
    Bing Du Xue Bao; 2011 Jul; 27(4):402-8. PubMed ID: 21874913
    [No Abstract]   [Full Text] [Related]  

  • 2. H5N1 influenza virus-like particle vaccine protects mice from heterologous virus challenge better than whole inactivated virus.
    Ren Z; Ji X; Meng L; Wei Y; Wang T; Feng N; Zheng X; Wang H; Li N; Gao X; Jin H; Zhao Y; Yang S; Qin C; Gao Y; Xia X
    Virus Res; 2015 Mar; 200():9-18. PubMed ID: 25599603
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pandemic H1N1 influenza virus-like particles are immunogenic and provide protective immunity to pigs.
    Pyo HM; Masic A; Woldeab N; Embury-Hyatt C; Lin L; Shin YK; Song JY; Babiuk S; Zhou Y
    Vaccine; 2012 Feb; 30(7):1297-304. PubMed ID: 22207090
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Principles underlying the development and use of live attenuated cold-adapted influenza A and B virus vaccines.
    Murphy BR; Coelingh K
    Viral Immunol; 2002; 15(2):295-323. PubMed ID: 12081014
    [No Abstract]   [Full Text] [Related]  

  • 5. A novel method to produce Influenza A virus matrix protein M1 Capsid Like Particles (CLPs).
    Baniasadi V; Lal SK
    J Virol Methods; 2014 Sep; 205():1-2. PubMed ID: 24797458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Enhanced Influenza VLP vaccines comprising matrix-2 ectodomain and nucleoprotein epitopes protects mice from lethal challenge.
    Gao X; Wang W; Li Y; Zhang S; Duan Y; Xing L; Zhao Z; Zhang P; Li Z; Li R; Wang X; Yang P
    Antiviral Res; 2013 Apr; 98(1):4-11. PubMed ID: 23416215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant loop region of hepatitis B core antigen: Insertion of multiple copies of M2e increases immunogenicity and protective efficiency.
    Ravin NV; Blokhina EA; Kuprianov VV; Stepanova LA; Shaldjan AA; Kovaleva AA; Tsybalova LM; Skryabin KG
    Vaccine; 2015 Jun; 33(29):3392-7. PubMed ID: 25937448
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
    Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
    Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Characterization of Humoral Responses Induced by an H7N9 Influenza Virus-Like Particle Vaccine in BALB/C Mice.
    Zhang L; Lu J; Chen Y; Shi F; Yu H; Huang C; Cui L; Shi Z; Jiao Y; Hu Y
    Viruses; 2015 Aug; 7(8):4369-84. PubMed ID: 26248076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in the development of universal influenza vaccines.
    Gilbert SC
    Influenza Other Respir Viruses; 2013 Sep; 7(5):750-8. PubMed ID: 22998622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunogenicity of H1N1 influenza virus-like particles produced in Nicotiana benthamiana.
    Shoji Y; Prokhnevsky A; Leffet B; Vetter N; Tottey S; Satinover S; Musiychuk K; Shamloul M; Norikane J; Jones RM; Chichester JA; Green BJ; Streatfield SJ; Yusibov V
    Hum Vaccin Immunother; 2015; 11(1):118-23. PubMed ID: 25483524
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunisation against influenza.
    Commun Dis Rep CDR Wkly; 1994 Jul; 4(29):135. PubMed ID: 7522813
    [No Abstract]   [Full Text] [Related]  

  • 13. Incorporation of conserved nucleoprotein into influenza virus-like particles could provoke a broad protective immune response in BALB/c mice and chickens.
    Xue C; Tian G; Chen X; Liu Q; Ma J; Xu S; Li X; Chen H; Cao Y
    Virus Res; 2015 Jan; 195():35-42. PubMed ID: 25312452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A cell-based backup to speed up pandemic influenza vaccine production.
    Lee MS; Hu AY
    Trends Microbiol; 2012 Mar; 20(3):103-5. PubMed ID: 22257962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assembly and immunological properties of a bivalent virus-like particle (VLP) for avian influenza and Newcastle disease.
    Shen H; Xue C; Lv L; Wang W; Liu Q; Liu K; Chen X; Zheng J; Li X; Cao Y
    Virus Res; 2013 Dec; 178(2):430-6. PubMed ID: 24050994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Avian influenza. 'Pandemic vaccine' appears to protect only at high doses.
    Enserink M
    Science; 2005 Aug; 309(5737):996. PubMed ID: 16099954
    [No Abstract]   [Full Text] [Related]  

  • 17. WHO recommendations on the composition of the 2015/16 influenza virus vaccines in the northern hemisphere.
    Eurosurveillance editorial team
    Euro Surveill; 2015 Mar; 20(9):. PubMed ID: 25764193
    [No Abstract]   [Full Text] [Related]  

  • 18. The use of inactivated influenza vaccine in children.
    Wright PF
    Semin Pediatr Infect Dis; 2006 Oct; 17(4):200-5. PubMed ID: 17055371
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meeting report VLPNPV: Session 10: Virus-like particle and nano-particle vaccines.
    Effio CL; Hubbuch J
    Hum Vaccin Immunother; 2014; 10(10):3080-2. PubMed ID: 25458914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Complexities in assessing the effectiveness of inactivated influenza vaccines.
    Kelly H; Steffens I
    Euro Surveill; 2013 Feb; 18(7):1. PubMed ID: 23449181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.